Valkyrie Clinical Trials
Los Angeles, CA
Accepting patients
IDP-023
Phase 1/2 Study of IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
- Natural Killer Cells (Allogeneic)
- Phase 1/2
Accepting patients